Revolution Medicines Financial Statements
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Revolution Medicines revenue and earnings
In fiscal 2025, Revolution Medicines generated $0 in revenue, up 0.0% from fiscal 2024. Revolution Medicines reported a net loss of $1.13 billion, compared with a loss of $600.1 million a year earlier. Diluted earnings per share came in at -$5.95.
Summary generated from market data by MetaCap's automated system. Methodology
Revolution Medicines income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 11.58M | 35.38M | 29.39M | 42.98M | 50.04M | 20.16M |
| Revenue growth (YoY) | — | -100.00% | -67.27% | +20.38% | -31.62% | -14.10% | +148.16% | — |
| Operating Expenses | 1.18B | 689.52M | 498.76M | 293.66M | 217.40M | 153.68M | 104.16M | 60.49M |
| Research & Development | 987.33M | 592.23M | 423.14M | 253.07M | 186.95M | 132.25M | 91.75M | 51.08M |
| Operating Income | -1.18B | -689.52M | -487.19M | -258.28M | -188.01M | -110.70M | -54.12M | -40.33M |
| Interest Expense | 24.23M | 0 | 0 | 0 | 12.00K | 71.00K | 106.00K | 116.00K |
| Other Income (Expense) | 51.07M | 88.68M | 47.29M | 9.15M | 917.00K | 2.17M | 2.08M | -1.46M |
| Pretax Income | -1.13B | -600.85M | -439.89M | -249.13M | -187.09M | -108.53M | -52.04M | -41.79M |
| Income Tax | 0 | -753.00K | -3.52M | -420.00K | 0 | -371.00K | -4.37M | — |
| Net Income | -1.13B | -600.09M | -436.37M | -248.71M | -187.09M | -108.16M | -47.66M | -41.79M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 | -21.24 |
| EPS (Diluted) | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 | -21.24 |
| Shares Outstanding (Basic) | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | 2.77M | 2.30M |
| Shares Outstanding (Diluted) | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | 2.77M | 2.30M |
| EBITDA | -1.17B | -682.97M | -482.14M | -254.31M | -184.93M | -108.09M | -51.85M | -38.76M |
| Operating Margin | — | — | -4207.12% | -730.01% | -639.70% | -257.54% | -108.15% | -200.00% |
| Net Margin | — | — | -3768.28% | -702.95% | -636.58% | -251.63% | -95.25% | -207.24% |
This table shows 8 annual periods of Revolution Medicines's income statement, from FY 2025 back to FY 2018, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RVMD's reporting calendar. What is a income statement?